Opinion on Therapy Area in Germany

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
Expert View
Expert View

APA 2012: cariprazine fails to offer a therapeutic breakthrough

Forest and Gedeon's cariprazine is a pharmacologically unique atypical antipsychotic in Phase III development for both schizophrenia and bipolar mania. Data presented at APA 2012 hint that while cariprazine appears to be effective in both indications, its tolerability and failure to address the broader bipolar depression patient population will hinder uptake.

Published By Datamonitor
15 May 2012
Expert View
Expert View

APA 2012: diagnostic overhaul will shape psychiatry drug markets

The DSM-5, the latest edition of the gold-standard diagnostic guidelines in psychiatry throughout the world, is due to be unveiled in May 2013. Given the huge size of the psychiatry drug market, any changes made to the diagnoses of conditions such as depression, bipolar disorders, and schizophrenia - however slight - will be of great interest to the pharmaceutical industry.

Published By Datamonitor
15 May 2012
Expert View
Expert View

APA 2012: Forest's latest antidepressants will have diverging fortunes

Pooled data released at the APA 2012 suggest that Forest's Viibryd combines a fast onset of antidepressant activity with a favorable side-effect profile, satisfying two important unmet needs in depression pharmacotherapy. Conversely, results from the Phase III program for levomilnacipran are less impressive, suggesting that the drug offers little benefit over other drugs in its class.

Published By Datamonitor
15 May 2012
Expert View
Expert View

APA 2012: standout schizophrenia and bipolar depression data for Latuda steal the show

New clinical data were presented at APA 2012 that showed that Latuda is effective as an adjunctive treatment for bipolar depression and may possess a procognitive effect in schizophrenia patients. These findings set Latuda apart from the competition and may allow the drug to shine in a fiercely competitive antipsychotics market.

Published By Datamonitor
15 May 2012
ResearchWire
ResearchWire

Arthritis: sales will hit $24 billion in 2007

Published By Datamonitor
23 Apr 2001
ResearchWire
ResearchWire

Asthma: prevalence to increase worldwide

Published By Datamonitor
28 Jan 2002
ResearchWire
ResearchWire

Asthma: two-thirds of patients suffer persistently

Published By Datamonitor
15 Apr 2005
ResearchWire
ResearchWire

Asthma: UK top for diagnosis, US bottom

Published By Datamonitor
04 Feb 2002
CommentWire
CommentWire

AstraZeneca/Targacept: another nail in the coffin for TC-5214

New top-line data show that the innovative nicotinic receptor antagonist TC-5214 has once again failed to demonstrate efficacy as an add-on to antidepressants in patients with major depressive disorder. Approval now seems highly unlikely, leaving Targacept without a lead candidate and AstraZeneca with a hefty loss.

Published By Datamonitor
20 Dec 2011
CommentWire
CommentWire

Aventis: cardiovascular success faces future threats

Lovenox and Delix/Tritace were both key products in 2001. While these blockbusters should remain strong revenue generators through 2004, they face serious market threats. Meanwhile, Aventis' new ACE/NEP inhibitor, expected to launch around 2004, could face strong competition from BMS' Vanlev, which is widely predicted to achieve blockbuster status despite regulatory problems.

Published By Datamonitor
13 Feb 2002

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.